Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "AstraZeneca-Pharma"

50 News Found

AstraZeneca backs next-gen cardiologists with India Coronary Conquest 2026
Healthcare | April 21, 2026

AstraZeneca backs next-gen cardiologists with India Coronary Conquest 2026

The programme has already drawn over 120 complex percutaneous coronary intervention (PCI) case submissions from across the country


AstraZeneca India, Telangana Govt partner for AI-led lung cancer screening in public hospitals
Digitisation | April 07, 2026

AstraZeneca India, Telangana Govt partner for AI-led lung cancer screening in public hospitals

MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations


AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder
Drug Approval | December 18, 2025

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder

The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India


AstraZeneca and Sun Pharma partner to expand hyperkalemia treatment in India
News | November 17, 2025

AstraZeneca and Sun Pharma partner to expand hyperkalemia treatment in India

Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names


FDA approves Alembic's Ticagrelor Tablets, 60 mg
Drug Approval | October 29, 2025

FDA approves Alembic's Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients


Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Drug Approval | May 03, 2025

Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,


AstraZeneca receives CDSCO approval to launch eculizumab in India
Drug Approval | January 17, 2025

AstraZeneca receives CDSCO approval to launch eculizumab in India

Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome


Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)
People | January 02, 2025

Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)

He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience


AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
News | May 28, 2024

AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr

Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth


Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
Drug Approval | January 03, 2024

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals